KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell ...
2020年4月1日 · Considering the very poor prognosis with currently available therapies in patients with relapsed or refractory mantle-cell lymphoma after treatment with a BTK inhibitor, we …
Three-Year Follow-Up of KTE-X19 in Patients With Relapsed
2023年1月20日 · Outcomes after a 3-year follow-up in the pivotal ZUMA-2 study of KTE-X19 in relapsed/refractory MCL are reported, including for subgroups by prior therapy (bendamustine …
ZUMA-2: Phase 2 multicenter study evaluating efficacy of kte-C19 …
2018年6月1日 · This phase 2, multicenter, open-label study examines efficacy and safety of KTE-C19, an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy, in pts with R/R …
2020年4月2日 · phase 2 ZUMA-2 trial to evaluate KTE-X19 in patients with relapsed or refractory mantle-cell lymphoma. Here, we report the efficacy and safety results from the ZUMA-2 trial. …
FDA approves brexucabtagene autoleucel for relapsed or …
On July 24, 2020, the Food and Drug Administration granted accelerated approval to brexucabtagene autoleucel (TECARTUS, Kite, a Gilead Company), a CD19-directed …
Three-Year Follow-Up of KTE-X19 in Patients With …
2022年6月4日 · Outcomes after a 3-year follow-up in the pivotal ZUMA-2 study of KTE-X19 in relapsed/refractory MCL are reported, including for subgroups by prior therapy (bendamustine …
Kite Presents Positive Results From Pivotal ZUMA 2 Trial in …
ZUMA-2 is a single-arm, multicenter, open-label Phase 2 study involving 74 enrolled/leukapheresed adult patients (≥18 years old) with MCL whose disease is refractory to …
Results from the phase II ZUMA-2 trial: CAR T therapy for MCL
The interim results of the phase II ZUMA-2 trial indicate that infusion of KTE-X19 CAR T cells leads to high and durable response rates in patients with R/R MCL, with an ORR of 93% and a …
Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2 …
In the ZUMA-2 single-arm trial, brexucabtagene autoleucel (brexu-cel; autologous anti-CD19 CAR T-cell therapy) demonstrated high rates of durable responses in patients with R/R MCL who …
Primary Analysis of ZUMA-2 Treatment of BTK Inhibitor-Naive …
2024年12月23日 · A primary analysis of ZUMA-2, reported at the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition, demonstrated durable responses to …